NCT06989840View on ClinicalTrials.gov

Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne

PHASE1RecruitingINTERVENTIONAL

Enrollment

128

Participants

Timeline

Start Date

May 19, 2025

Primary Completion Date

December 1, 2025

Study Completion Date

January 1, 2026

Conditions

Acne

Interventions

DRUG

TVB-3567

Orally administered capsule

DRUG

Placebo

Orally administered capsule

Trial Locations (1)

85283

RECRUITING

Celerion, Inc., Tempe

All Listed Sponsors

lead

Sagimet Biosciences Inc.

INDUSTRY